AFJK · XBRL financial data

Aimei Health Technology financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AFJK's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Operating income (loss)	—	(154)	(309)	(200)	(402)*	(413)	(42)	(130)	(251)*	(62)	(192)
Income tax expense (benefit)	year only	0	0	0	0*	0	0	0	0*	0	0
Net income (loss)	175*	756	609	744	444*	185	425	352	98*	45	(83)

Fiscal quarters (AFJK's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	581	414	158	104	28	7	2	3	3	19	1
Total current assets	581	481	204	124	30	8	45	25	3	19	44
Total assets	70,471	71,280	71,922	72,785	73,815	43,603	44,556	45,469	12,103	12,295	12,532
Accrued liabilities	25	78	59	142	300	457	309	293	448	436	513
Total current liabilities	25	78	111	231	817	1,686	2,214	2,774	3,372	3,518	3,839
Total liabilities	715	768	801	921	1,507	2,376	2,904	3,464	4,062	4,208	4,529
Accumulated deficit	(134)	(288)	(597)	(797)	(1,477)	(2,368)	(2,860)	(3,440)	(4,059)	(4,190)	(4,485)
Total stockholders' equity	(134)	(288)	(597)	(797)	(1,477)	(2,368)	(2,859)	(3,439)	(4,059)	(4,189)	(4,485)
Total liabilities and equity	70,471	71,280	71,922	72,785	73,815	43,603	44,556	45,469	12,103	12,295	12,532
Common shares outstanding (cover page) thousands of shares	9,026	9,026	9,026	9,026	6,122	6,122	6,122	6,122	3,166	3,166	3,166

Fiscal quarters (AFJK's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	175*	756	609	744	444*	185	425	352	98*	45	(83)
Net cash from operating activities	—	(167)	(256)*	(54)*	(195)*	(224)	(202)*	(96)*	(43)*	(75)	(157)*
Net cash from investing activities	—	—	—	—	year only	30,788	(450)*	(450)*	33,692*	(69)	(103)*
Proceeds from issuing common stock	0*	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	70,261*	—	—	—	year only	(30,585)	647*	547*	(33,649)*	159	243*
Net change in cash	571*	(167)	(256)*	(54)*	(75)*	(21)	(5)*	1*	(0)*	16	(17)*

SIC 6770 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 6770 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aimei Health Technology	1.5	not reported	(157)*	3.2M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Bayview Acquisition	51	not reported	0.4*	2.6M	—	Q2 FY26 10-QJun 30, 2026
Starry Sea Acquisition	6.1	not reported	(52)*	7.6M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Rising Dragon Acquisition	8.7	not reported	(213)*	3.4M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
UY Scuti Acquisition	8.8	not reported	(0)	5.2M	225.8 quarters	Q1 FY27 10-QJun 30, 2026
ASPAC III Acquisition	634	not reported	(37)*	not reported	17.3 quarters	Q2 FY26 10-QJun 30, 2026
Cayson Acquisition	54	not reported	(9.9)*	5.3M	5.5 quarters	Q2 FY26 10-QJun 30, 2026
YHN Acquisition I	27	not reported	(116)*	4.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Columbus Acquisition Corp/Cayman Islands	8.4	not reported	(196)*	4.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.